SCHEMBL7122672

SCHEMBL7122672

O=C1c2ccccc2C(=O)c2c(NCC=CO)cccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.53
L3MBTL1 Q9Y468 3/20 0.53
MAPK1 P28482 3/20 0.53
EGFR P00533 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
RAB9A P51151 2/20 0.53
PABPC1 P11940 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
POLB P06746 3/20 0.52
ALDH1A1 P00352 3/20 0.52
BLM P54132 2/20 0.52
RAD52 P43351 2/20 0.52
LMNA P02545 1/20 0.52
HTT P42858 1/20 0.52
RECQL P46063 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
MAOA P21397 1/20 0.51
NSD2 O96028 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7129853 0.85 MAPT (0.53) MAPTL3MBTL1MAPK1EGFRSMN1; SMN2
SCHEMBL1906212 0.81 MAPT (0.56) MAPTL3MBTL1MAPK1EGFRSMN1; SMN2
SCHEMBL13995639 0.79 MAPT (0.65) MAPTL3MBTL1MAPK1EGFRSMN1; SMN2
SCHEMBL9893976 0.78 MAPT (0.50) MAPTL3MBTL1MAPK1EGFRSMN1; SMN2
SCHEMBL9893975 0.78 MAPT (0.50) MAPTL3MBTL1MAPK1EGFRSMN1; SMN2
SCHEMBL30066019 0.77 MAPT (0.60) MAPTL3MBTL1MAPK1EGFRSMN1; SMN2
SCHEMBL4732627 0.76 MEN1 (0.72) MAPTL3MBTL1MAPK1EGFRSMN1; SMN2
SCHEMBL8053208 0.76 MAPT (0.66) MAPTL3MBTL1MAPK1EGFRSMN1; SMN2
SCHEMBL28307733 0.76 MAPT (0.61) MAPTL3MBTL1MAPK1EGFRSMN1; SMN2
SCHEMBL7156586 0.76 MAPT (0.66) MAPTL3MBTL1MAPK1EGFRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4230619-A None JP disclosed
US-20030130272-A1 Anthracene derivatives as anti-cancer agents BTG INTERNATIONAL LIMITED (GB) 2003-07-10 US disclosed
EP-1244624-A1 ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS BTG INTERNATIONAL LIMITED (GB) 2002-10-02 EP disclosed
WO-2001044190-A1 ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS BTG INTERNATIONAL LIMITED (GB) 2001-06-21 WO disclosed
JP-H04230619-A HAIR DYEING COMPOSITION CONTAINING ANTHRAQUINONE COMPOUND L'OREAL SA 1992-08-19 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130272-A1 Anthracene derivatives as anti-cancer agents TOP2B, TOP1, TOP2A MAPT 4884/4885L3MBTL1 2430/4885MAPK1 3848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.